R57 Sp. z o.o.

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Crohn's disease4 trials
• Ulcerative colitis3 trials
• Multiple sclerosis1 trial
• Myasthenia gravis1 trial
• Type 2 diabetes1 trial

Phase

• Phase 24 trials
• Phase 34 trials
• Phase 11 trial

Status

• Recruiting6 trials
• Not yet recruiting2 trials
• Active, not recruiting1 trial

Lead sponsor

• Hoffmann-La Roche2 trials
• Dianthus Therapeutics1 trial
• Eli Lilly & Co.1 trial
• Eli Lilly and Company1 trial
• Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)1 trial
• and 3 more

Running trials

• Not yet recruiting

  A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both

  NCT07931599· Phase 3· Novo Nordisk A/S· Source

• Not yet recruiting

  A Biosimilar Trial to Investigate PK, PD, Safety With PB018 Versus US-licensed Ocrevus and EU-approved Ocrevus

  NCT07606521· Phase 1· Polpharma Biologics International AG· Source

• Recruiting

  A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)

  NCT07647510· Phase 3· Dianthus Therapeutics· Source

• Recruiting

  A study of LY4268989 in participants with Moderately to Severely Active Ulcerative Colitis (EMERALD-3)

  2025-524404-29-00· Phase 2· Eli Lilly & Co.· Source

• Recruiting

  A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

  NCT07483073· Phase 2· Eli Lilly and Company· Source

• Recruiting

  Confirmatory Clinical Study in Active Ulcerative Colitis

  NCT07296315· Phase 2· MRM Health NV· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819891· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819878· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease

  NCT06226883· Phase 2· Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Crohn's disease3 recruiting
• Ulcerative colitis3 recruiting
• Multiple sclerosis1 recruiting
• Myasthenia gravis1 recruiting
• Type 2 diabetes1 recruiting